Selectiveinhibitorofmultidrugresistance-associatedprotein1(MRP1)andP-glycoprotein(P-gp).IncreasesthesensitivityofMRP1-overexpressingtumorcells(MCF7/VP)todoxorubicin(Cat.No.2252),vincristine(Cat.No.1257)andetoposide(Cat.No.1226)by3.8-,14.6-and11.6-foldrespectively.Increasestheefficacyofvincristineandetoposideinmurinemodelsofneuroblastomainvivo.DoesnotsensitizeMRP2,MRP3,MRP4orMRP5transporterstoknownsubstrates.
ReversanisalsoofferedaspartoftheTocriscreenPlus.FindoutmoreaboutcompoundlibrariesavailablefromTocris.
| M.Wt | 441.52 |
| Formula | C26H27N5O2 |
| Storage | StoreatRT |
| Purity | ≥99%(HPLC) |
| CASNumber | 313397-13-6 |
| PubChemID | 2298706 |
| InChIKey | JTRXWCLQFAZHGP-UHFFFAOYSA-N |
| Smiles | O=C(NCCCN5CCOCC5)C2=C1N=C(C4=CC=CC=C4)C=C(C3=CC=CC=C3)N1N=C2 |
Thetechnicaldataprovidedaboveisforguidanceonly.ForbatchspecificdatarefertotheCertificateofAnalysis.
AllTocrisproductsareintendedforlaboratoryresearchuseonly.
| Solvent | MaxConc.mg/mL | MaxConc.mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 11.04 | 25 | |
| ethanol | 2.21 | 5 |
Thefollowingdataisbasedontheproductmolecularweight441.52.Batchspecificmolecularweightsmayvaryfrombatchtobatchduetosolventofhydration,whichwillaffectthesolventvolumesrequiredtopreparestocksolutions.
| Concentration/SolventVolume/Mass | 1mg | 5mg | 10mg |
|---|---|---|---|
| 1mM | 2.26mL | 11.32mL | 22.65mL |
| 5mM | 0.45mL | 2.26mL | 4.53mL |
| 10mM | 0.23mL | 1.13mL | 2.26mL |
| 50mM | 0.05mL | 0.23mL | 0.45mL |



